» Articles » PMID: 32040344

Elevated Expression of Is Associated with Lung Adenocarcinoma Carcinogenesis and Poor Prognosis

Overview
Journal DNA Cell Biol
Publisher Mary Ann Liebert
Date 2020 Feb 11
PMID 32040344
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant expression of plays an oncogenic role in several types of cancer. However, the functions of in lung adenocarcinoma (LUAD) remain unclear. Here, we investigated the regulatory function, clinical value, and prognostic significance of in LUAD patients. The gene expression and DNA methylation data of LUAD tumor and paracancerous tissues were obtained from The Cancer Genome Atlas (TCGA) database. The association between expression and clinicopathological variables was analyzed. The results showed that was highly expressed in LUAD tumor compared with paracancerous tissues, which was positively correlated with the race ( = 0.0448), tumor stage ( = 0.0191), and survival status ( < 0.001). Furthermore, the expression of was able to be regulated by the methylation in promoter region, which was positively associated with the overall survival. Furthermore, we explored the related pathways through which affects the pathogenesis and prognosis of LUAD by gene set enrichment analysis, and found that might affect the clinical manifestations of LUAD by regulating the P53 signaling pathway. In the future, we would focus on exploring the molecular mechanism of in the regulation of the occurrence and development of LUAD to provide a research basis for the screening of methylation markers related to the treatment and prognosis.

Citing Articles

Unveiling Varied Cell Death Patterns in Lung Adenocarcinoma Prognosis and Immunotherapy Based on Single-Cell Analysis and Machine Learning.

Song Z, Zhang W, Zhu M, Wang Y, Zhou D, Cao X J Cell Mol Med. 2024; 28(22):e70218.

PMID: 39602465 PMC: 11601877. DOI: 10.1111/jcmm.70218.


Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma.

Luo Z, Li Y, Xu B, Yu T, Luo M, You P Exp Hematol Oncol. 2024; 13(1):77.

PMID: 39103908 PMC: 11302107. DOI: 10.1186/s40164-024-00546-y.


Comprehensive analysis of exosome gene LYPD3 and prognosis/immune cell infiltration in lung cancer.

Xin T, Zheng C, Li G, Xu X, Zhang J, Jia C Transl Cancer Res. 2024; 13(3):1394-1405.

PMID: 38617517 PMC: 11009804. DOI: 10.21037/tcr-23-1557.


Constructing an APOBEC-related gene signature with predictive value in the overall survival and therapeutic sensitivity in lung adenocarcinoma.

Luo Y, Wang H, Zhong J, Shi J, Zhang X, Yang Y Heliyon. 2023; 9(11):e21336.

PMID: 37954334 PMC: 10637964. DOI: 10.1016/j.heliyon.2023.e21336.


LY6/PLAUR domain containing 3 (LYPD3) maintains melanoma cell stemness and mediates an immunosuppressive microenvironment.

Hu Y, Wu K, Liu Y, Zhang Q, Shen H, Ji J Biol Direct. 2023; 18(1):72.

PMID: 37924160 PMC: 10623712. DOI: 10.1186/s13062-023-00424-3.